Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Core Viewpoint - Pharvaris is advancing its late-stage biopharmaceutical candidate, deucrictibant, which shows promise as a preferred therapy for hereditary angioedema (HAE) treatment and prevention, based on recent clinical data presented at multiple conferences [1][2]. Group 1: Clinical Efficacy and Data Presentation - Deucrictibant demonstrated substantial symptom resolution in 78.6% of participants within 24 hours after a single dose, compared to 22.4% for placebo [2][4]. - The treatment satisfaction questionnaire indicated that participants reported higher satisfaction with deucrictibant's effectiveness compared to placebo, aligning with high-efficacy injectable therapies [4]. - Ongoing studies aim to expand the long-term safety and efficacy database of deucrictibant, particularly regarding its use in laryngeal attacks [2][3]. Group 2: Product Development and Future Plans - Pharvaris is developing two formulations of deucrictibant: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic use [6][7]. - The company is committed to exploring additional indications and expanding its product pipeline to address unmet needs in the HAE community [2][5]. - Pharvaris aims to leverage real-world evidence to better understand treatment behaviors and needs within the HAE patient population [3].